The Enzyme Replacement Therapy Market is anticipated to reach a value of US$ 9.3 billion in 2022 and, with a CAGR of 6.7%, US$ 13.8 billion by the end of 2028. Revenue from enzyme replacement therapy (ERT) represents over 63% of the market for hormone replacement globally. The usage of enzyme replacement therapy has been significantly influenced by the rise in the prevalence of uncommon disorders, and it is anticipated that medical research will further speed up this development.
Increasing per capita healthcare expenditure in North America is expected to push market revenue growth. The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populous regions of Asia Pacific and China is expected to play an important role in driving revenue growth of the global enzyme replacement therapy market.
Download Now: Explore the Booming Enzyme Replacement Therapy Market with Our Sample Report! @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3167
Global Enzyme Replacement Therapy Market: Regional Insights
With nearly 25%-30% market share, North America dominated the global enzyme replacement therapy market in 2017, partly due to the presence of leading market players in the region. In developing regions such as Latin America, advancements in medical facilities are helping the region cope with healthcare crisis. Medical facilities in Brazil are equivalent with hospitals in the United States, with some even exceeding American standards. Brazil offers everything from large, full service hospitals to smaller, intimate private clinics.
Brazil has developed into a centre of excellence for healthcare in Latin America, with major universities that support research, teaching and training of medical professionals. Western Europe is the second largest market globally and is expected to be valued at US$ 2,893.2 Mn by 2028, with France, Italy and Spain projected to witness significant growth rates. Japan is expected to be the third largest market for enzyme replacement therapy.
Global Enzyme Replacement Therapy Market: Segmentation & Forecast
The global enzyme replacement therapy market has been segmented on the basis of therapeutic condition, route of administration, distribution channel and region. Therapeutic conditions in the enzyme replacement therapy market include fabry disease, gaucher disease, mucopolysaccharidosis, pompe disease, lysosomal acid lipase deficiency and others.
Beyond the surface-level: Understanding the underlying assumptions of the study. By Asking our specialist @ https://www.futuremarketinsights.com/ask-question/rep-gb-3167
Globally, the mucopolysaccharidosis therapeutic condition is the most attractive segment. Injectable segment remains the most lucrative route of administration in the enzyme replacement therapy market. Among all distribution channels for enzyme replacement therapy, speciality treatment pharmacies are expected to be the most lucrative, followed by hospital pharmacies.
Key Research Findings
Enzyme replacement therapy is used in the treatment of rare diseases and the global market is projected to create incremental opportunity of US$ 6,448.3 Mn between 2022 and 2028
When compared to other established markets such as North America, the enzyme replacement therapy markets in Japan and Western Europe are expected to witness fast and steady growth, partly due to the increasing governmental support and growing demand for enzyme replacement therapy for the treatment of rare diseases.
Global Enzyme Replacement Therapy Market: Competitive Landscape
- Sanofi S.A. (Genzyme Corporation)
- Shire plc.
- Pfizer Inc.
- Alexion Pharmaceuticals Inc.
- BioMarin Pharmaceutical Inc.
- Ultragenyx Pharmaceutical Inc.
- Johnson & Johnson Services Inc.
- Allergan plc.
- Leadiant Biosciences Inc.
Didn’t find the data you are looking for? Our experts provide you customized reports @ https://www.futuremarketinsights.com/customization-available/rep-gb-3167
Key Segments of Enzyme Replacement Therapy Industry Survey
Enzyme Replacement Therapy Market by Therapeutic Condition:
- Enzyme Replacement Therapy for Fabry Disease
- Enzyme Replacement Therapy for Gaucher Disease
- Enzyme Replacement Therapy for Mucopolysaccharidosis
- MPS I
- MPS II (Hunter Syndrome)
- MPS IVA (Morquio Syndrome, Type A)
- MPS VI (Maroteaux-Lamy Syndrome)
- MPS VII (Sly Syndrome)
- Enzyme Replacement Therapy for Pompe Disease
- Enzyme Replacement Therapy for Lysosomal Acid Lipase Deficiency
- Others
Enzyme Replacement Therapy Market by Route of Administration:
- Oral Enzyme Replacement Therapy
- Injectable Enzyme Replacement Therapy
Enzyme Replacement Therapy Market by Distribution Channel:
- Hospital Pharmacies
- Specialty Treatment Pharmacies
- Retail Pharmacies
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
